Interleukin-27/IL-27 Recombinant Protein | IL-27 recombinant protein

Recombinant Mouse Interleukin-27/IL-27 Protein (C-6His)

Cat. Num. AAA2553559

• Gene Names: Ebi3; EBI-3; IL-27
• Purity: >90% as determined by reducing SDS-PAGE.
• Synonyms: Interleukin-27/IL-27; Recombinant Mouse Interleukin-27/IL-27 Protein (C-6His); Interleukin-27 subunit alpha; IL-27 subunit alpha; IL-27-A; IL27-A; p28; Il27; Il27a; Interleukin-27 subunit beta; Ebi3; IL-27 subunit beta; IL-27B; Epstein-Barr virus-induced gene 3 protein homolog; Il27b; IL-27 recombinant protein

• Host: Human Cells
• Purity/Purification: >90% as determined by reducing SDS-PAGE.
• Form/Format: Lyophilized from a 0.2 mum filtered solution of PBS, 2mM EDTA, 5% Mannitol, pH 7.4.
• Sequence Positions: Tyr19-Pro228 & Phe29-Ser234
• Sequence Length: 228

• Species: Mouse
• Endotoxin: <1.0 EU per mug as determined by LAL test.
• Fusion Tag: C-6His
• Preparation and Storage: Lyophilized protein should be stored at < -20 degree C, though stable at room temperature for 3 weeks.; Reconstituted protein solution can be stored at 4-7 degree C for 2-7 days. Aliquots of reconstituted samples are stable at < -20 degree C for 3 months.

Related Product Information for IL-27 recombinant protein

IL-27 is a heterodimeric cytokine which belongs to the IL-6/IL-12 family of long type I cytokines. It is expressed on monocytes, endothelial cells and dendritic cells. IL-27 is an early product of activated antigen-presenting cells and drives rapid clonal expansion of naive CD4(+) T cells and plays a role in the early regulation of Th1 cells initiation which drives efficient adaptive immune response. IL-27 potentiates the early phase of TH1 response and suppresses TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. IL-27 has an antiproliferative activity on melanomas through WSX-1/STAT1 signaling. Thus, IL-27 protein may be an attractive candidate as an antitumor agent applicable to cancer immunotherapy. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. IL-27 has also an effect on cytokine production. It suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9.

NCBI and Uniprot Product Information

• NCBI GI #: 7657052
• NCBI GeneID: 50498
• NCBI Accession #: NP_056581.1
• NCBI GenBank Nucleotide #: NM_015766.2
• UniProt Accession #: O35228; Q8K3I6
• Molecular Weight: Molecular Mass: 49 kDa; Actual Protein Molecular Mass: 60-65 kDa
• NCBI Official Full Name: interleukin-27 subunit beta
• NCBI Official Synonym Full Names: Epstein-Barr virus induced gene 3
• NCBI Official Symbol: Ebi3
• NCBI Official Synonym Symbols: EBI-3; IL-27
• NCBI Protein Information: interleukin-27 subunit beta
• UniProt Protein Name: Interleukin-27 subunit beta
• UniProt Gene Name: Ebi3
• UniProt Synonym Gene Names: Il27b; IL-27 subunit beta; IL-27B

Uniprot Description

Associates with IL27 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines.